Autoimmune hemolytic anemia (IMHA) in dogs happens when the immune system mistakenly attacks and destroys the body’s own red blood cells. In roughly 60 to 75 percent of cases, no underlying trigger is ever identified, and the condition is classified as primary or idiopathic. The remaining cases are secondary, meaning something identifiable pushed the immune system into overdrive: an infection, a medication, cancer, or even a recent vaccination.
How the Immune System Turns on Red Blood Cells
Normally, the immune system uses antibodies to tag foreign invaders like bacteria or viruses for destruction. In IMHA, those antibodies latch onto the surface of the dog’s own red blood cells instead. Once tagged, the red blood cells are either destroyed directly in the bloodstream or filtered out and broken down by the spleen and liver. The body tries to replace them by ramping up production in the bone marrow, but in many cases it simply can’t keep pace with the rate of destruction. The result is a rapidly dropping red blood cell count, which means less oxygen reaching the dog’s tissues and organs.
This process also produces large amounts of bilirubin, a waste product from broken-down red blood cells. That’s why jaundice (a yellowing of the gums, whites of the eyes, or skin) is one of the hallmark signs of IMHA. The urine may also turn dark orange or brown as the body tries to flush out the excess pigment.
Primary IMHA: When There’s No Clear Cause
Most dogs with IMHA fall into the primary category, meaning the immune system misfires without any obvious provocation. Why this happens isn’t fully understood, but it likely involves a combination of genetic susceptibility and environmental factors that tip the immune system out of balance. The dog’s body essentially loses the ability to distinguish “self” from “threat,” and red blood cells become the target. Because no trigger can be pinpointed, treatment focuses on suppressing the immune response directly.
Breeds and Dogs at Higher Risk
IMHA can affect any dog, but certain breeds carry a significantly higher risk. A study published in the Journal of the American Veterinary Medical Association identified Cocker Spaniels, Bichon Frises, Miniature Pinschers, Rough-coated Collies, and Finnish Spitz as breeds with elevated susceptibility. Female dogs are about twice as likely to develop IMHA as males. Most affected dogs are middle-aged, typically between 2 and 8 years old, though it can appear at any age.
The breed clustering strongly suggests a genetic component. Dogs in these predisposed breeds may have inherited immune system traits that make them more prone to the kind of misdirected antibody response that drives IMHA. If your dog belongs to one of these breeds, it’s worth being familiar with early symptoms like sudden lethargy, pale gums, rapid breathing, or dark urine.
Infections That Can Trigger IMHA
Certain infections can set off secondary IMHA by altering the surface of red blood cells or by broadly overstimulating the immune system. The strongest evidence points to tick-borne parasites, particularly Babesia gibsoni, a microscopic organism that invades red blood cells directly. When the immune system mounts a response against the parasite, it can also begin targeting healthy red blood cells in the crossfire.
Other tick-borne and vector-borne organisms, including heartworm, Ehrlichia, Borrelia (the agent behind Lyme disease), Bartonella, and Leishmania, have been investigated as potential IMHA triggers. However, according to an ACVIM consensus statement reviewing the available evidence, the link between these agents and IMHA in dogs is weak or difficult to quantify. That doesn’t mean infection is irrelevant in an individual dog’s case, but the data supporting a direct causal relationship is strongest for Babesia.
Vaccines as a Possible Trigger
Vaccination has been studied as a potential trigger for IMHA, and the evidence suggests a real but uncommon association. In a study of 58 dogs with IMHA, 26 percent had been vaccinated within one month of developing the disease, with symptoms appearing an average of 13 to 14 days after the shot. In contrast, healthy control dogs showed no similar spike in illness following vaccination. The window of concern appears to be roughly the first four weeks post-vaccination.
This doesn’t mean vaccines cause IMHA in most dogs. The vast majority of vaccinated dogs never develop the condition. But for dogs who have already had an episode of IMHA, or who belong to a high-risk breed, veterinarians often recommend adjusting vaccination schedules. This might mean running antibody titer tests to check existing immunity rather than automatically re-vaccinating, or spacing out vaccines that would otherwise be given together.
Medications and Other Secondary Triggers
Certain medications can trigger IMHA by binding to the surface of red blood cells and making them look foreign to the immune system. Historically implicated drugs include some antibiotics (particularly sulfonamides and cephalosporins), anti-inflammatory medications, and certain parasite preventatives, though drug-triggered IMHA is considered relatively rare. If your dog develops signs of anemia shortly after starting a new medication, that timing is important information for your vet.
Cancer is another recognized trigger. Tumors involving the immune system, particularly lymphoma and hemangiosarcoma, can disrupt normal immune regulation and lead to secondary IMHA. In dogs diagnosed with IMHA, your vet will typically screen for underlying cancer, especially in older dogs, because treating the anemia alone won’t resolve the problem if a tumor is driving the immune attack.
Why Blood Clots Are the Biggest Danger
The most life-threatening complication of IMHA isn’t the anemia itself. It’s blood clots. When red blood cells are destroyed in large numbers, the debris and inflammatory signals in the bloodstream activate the clotting system. Dogs with IMHA are in a state of heightened clot risk, and clots that form in the lungs (pulmonary thromboembolism) are the leading cause of death. In one retrospective study of 104 dogs with IMHA, 60 percent of deaths were attributed to thromboembolic events. The remaining deaths resulted from a failure to respond to treatment or progressive clinical decline.
This is why dogs hospitalized with IMHA typically receive blood-thinning medications alongside immune-suppressing drugs. The goal is twofold: stop the immune attack on red blood cells, and prevent clots from forming while the body is in crisis.
What Survival Looks Like
IMHA is a serious diagnosis, but many dogs do survive. In a large Irish study tracking 104 dogs over nearly two decades, the mortality rate was 16 percent at one month and 31 percent at three months. The first few weeks are the most dangerous. Dogs that survive past the three-month mark have a dramatically better outlook, with a median survival time of over seven years in that study.
The initial treatment period typically involves hospitalization with blood transfusions if the anemia is severe, along with medications that suppress the immune system to halt the destruction of red blood cells. Once stabilized, most dogs continue on immune-suppressing medication at home for months, with the dose gradually tapered as blood counts recover. Relapses are possible, particularly if medication is reduced too quickly, so regular blood work monitoring is a normal part of long-term management.
Dogs with secondary IMHA generally have a better prognosis when the underlying trigger can be identified and addressed. Removing the offending drug, treating an infection, or managing cancer can resolve the immune attack at its source, whereas primary IMHA requires ongoing immune suppression because the root cause remains unknown.